Cardiovascular Pharmacogenomics: Hypertension

2008-2009 Personalized Medicine Visiting Professor Lecture Series

View Johnson Lecture (Flash)


The George Washington University’s George Washington University Heart & Vascular Institute & McCormick Genomics Center are pleased to host a CME event, with the Personalized Medicine Coalition, an educational and advocacy organization, as our co-sponsor. Our keynote speaker is Dr. Julie Johnson who will address “Cardiovascular Pharmacogenomics: Hypertension.”

The keynote address will be followed by an informal and interactive discussion with the keynote presenter and guest panelists. The program is open to attendees at no cost and offers CME credit


“Cardiovascular Pharmacogenomics: Hypertension”

Dr. Julie Johnson is the V. Ravi Chandran Professor of Pharmaceutical Sciences, Professor and Chair of the Department of Pharmacy Practice, Professor of Pharmaceutics and Professor of Medicine (Cardiovascular Medicine) at the University of Florida Colleges of Pharmacy and Medicine, and Director, University of Florida Center for Pharmacogenomics.
There are numerous drugs available for the treatment of hypertension, yet selection of a specific agent for a given patient is often empiric. Most data indicate only about 40% of hypertensives have their blood pressure controlled to < 140/90 mmHg, suggesting that the empiric approach to management may be suboptimal. Individualization of therapy may improve management of hypertension and pharmacogenetics is an approach where the patient’s genetic information might be used to guide therapy selections. This presentation will focus on Dr. Johnson’s work in hypertension pharmacogenetics, highlighting data from genetic associations with both the blood pressure response, and longterm cardiovascular outcomes. These data suggest that in the future it might be possible to utilize genetic information to aid in selection of therapy for hypertensive patients. Agenda

12 noon – 1:00 p.m.—Keynote Address

1:00 p.m. – 2:30 p.m. — Luncheon and Panel Discussion

Learning Objectives

After Dr. Johnson’s lecture, participants will be able to:

  • Describe the clinical potential for use of genetic information to guide drug therapy selection in hypertension,
  • Discuss existing data that suggests genetics may be an important determinant of responses to antihypertensive drugs,
  • Evaluate the processes by which pharmacogenetics might be translated to practice in the management of hypertension.

CME Credit

The George Washington Medical Center designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in this activity.


The George Washington University Hospital
900 23rd Street, NW
Washington, DC 20037

Luncheon & Panel Discussion
Marvin Center
The George Washington University
800 21st Street, NW, 4th floor, Room 403
Washington, DC 20052


To register for this program, please E-mail your full name, title, affiliation, and contact information to:

Seating is limited, therefore registration is required for all participants. Registrations will be accepted until February 1, 2009. After February 1, 2009, please call 202-315-3296 for availability.

Questions? Contact: VRS Meetings & Events Inc at 202-315-3296.


Program support provided by the following:
Pfizer, Merck, Forest Laboratories, Novartis, Merck/Schering-Plough Pharmaceuticals, deCODE genetics, Corgenix, Affymetrix, Celera, St. Jude Medical, Medtronic